药康生物
(688046)
| 流通市值：88.19亿 | | | 总市值：88.19亿 |
| 流通股本：4.10亿 | | | 总股本：4.10亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 208,076,700 | 793,389,024.92 | 575,576,818.48 | 374,808,989.09 |
| 营业收入 | 208,076,700 | 793,389,024.92 | 575,576,818.48 | 374,808,989.09 |
| 二、营业总成本 | 156,814,985.14 | 624,226,092.52 | 446,747,545.25 | 287,113,871.94 |
| 营业成本 | 74,769,634.14 | 284,431,292.73 | 207,114,573.64 | 133,900,946.59 |
| 税金及附加 | 1,231,370.96 | 4,994,316.82 | 2,793,764.33 | 1,639,447.13 |
| 销售费用 | 25,271,168.4 | 111,542,321.37 | 80,302,657.58 | 52,544,519.61 |
| 管理费用 | 33,742,969.01 | 134,494,265.09 | 97,781,921.87 | 63,520,904.6 |
| 研发费用 | 19,866,061.07 | 92,057,494.08 | 61,991,519.51 | 39,375,707.47 |
| 财务费用 | 1,933,781.56 | -3,293,597.57 | -3,236,891.68 | -3,867,653.46 |
| 其中:利息费用 | 1,687,548.27 | 6,077,607.15 | 4,589,636.57 | 2,856,768.62 |
| 其中:利息收入 | 3,486,378.34 | 10,559,616.8 | 7,248,137.3 | 4,885,223.44 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 483,037.54 | 693,494.32 | 2,139,933.56 | 372,000.14 |
| 加:投资收益 | 6,956,889.86 | 8,746,616.58 | 4,253,017.63 | 1,351,054.93 |
| 资产处置收益 | -1,230.7 | -36,167.9 | -35,525.54 | -25,422.09 |
| 资产减值损失(新) | -3,677,661.16 | -19,772,588.85 | -13,112,374.01 | -8,308,552.96 |
| 信用减值损失(新) | -3,347,162.02 | -9,793,733.44 | -12,298,710.83 | -8,906,176.93 |
| 其他收益 | 1,880,170.81 | 16,117,548.85 | 10,514,550.34 | 5,347,148.49 |
| 四、营业利润 | 53,555,759.19 | 165,118,101.96 | 120,290,164.38 | 77,525,168.73 |
| 加:营业外收入 | 0.42 | 6,454.56 | 4,054.07 | 0.44 |
| 减:营业外支出 | 744.01 | 202,348.36 | 133,412.66 | 82,948.48 |
| 五、利润总额 | 53,555,015.6 | 164,922,208.16 | 120,160,805.79 | 77,442,220.69 |
| 减:所得税费用 | 6,451,219.68 | 22,285,401.85 | 10,260,731.19 | 6,536,743.55 |
| 六、净利润 | 47,103,795.92 | 142,636,806.31 | 109,900,074.6 | 70,905,477.14 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 47,103,795.92 | 142,636,806.31 | 109,900,074.6 | 70,905,477.14 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 47,103,795.92 | 142,636,806.31 | 109,900,074.6 | 70,905,477.14 |
| 扣除非经常损益后的净利润 | 38,814,249.57 | 117,244,922.02 | 92,785,070.32 | 62,925,408.29 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.12 | 0.35 | 0.27 | 0.17 |
| (二)稀释每股收益 | 0.12 | 0.35 | 0.27 | 0.17 |
| 八、其他综合收益 | 1,472,862.18 | -1,566,598.08 | -471,982.53 | -555,105.94 |
| 归属于母公司股东的其他综合收益 | 1,472,862.18 | -1,566,598.08 | -471,982.53 | -555,105.94 |
| 九、综合收益总额 | 48,576,658.1 | 141,070,208.23 | 109,428,092.06 | 70,350,371.2 |
| 归属于母公司股东的综合收益总额 | 48,576,658.1 | 141,070,208.23 | 109,428,092.06 | 70,350,371.2 |
| 公告日期 | 2026-04-23 | 2026-04-23 | 2025-10-23 | 2025-08-23 |
| 审计意见(境内) | | 标准无保留意见 | | |